HOUSE 3537117th CongressBecame Public Law No: 117-79.

Accelerating Access to Critical Therapies for ALS Act

Last Action: 12/23/2021

Actions

2021-12-23Became Public Law No: 117-79.
2021-12-23Became Public Law No: 117-79.
2021-12-23Signed by President.
2021-12-23Signed by President.
2021-12-23Presented to President.
2021-12-23Presented to President.
2021-12-17Message on Senate action sent to the House.
2021-12-16Passed Senate without amendment by Voice Vote. (consideration: CR S9242)
2021-12-16Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.(consideration: CR S9242)
2021-12-09Received in the Senate, read twice.
2021-12-08Motion to reconsider laid on the table Agreed to without objection.
2021-12-08On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415). (text: CR H7509-7511)
2021-12-08Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 423 - 3 (Roll no. 415).(text: CR H7509-7511)
2021-12-08Considered as unfinished business. (consideration: CR H7535-7536)
2021-12-08At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.

Showing 15 of 20 actions. Full history on Congress.gov.

CRS Summary

As of 2021-12-23 (49)

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials.

The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases.

HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases.

The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases.

The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Cosponsors (20)

Jeff Fortenberry (R-NE)
Brendan Boyle (D-PA)
Seth Moulton (D-MA)
Mike Garcia (R-CA)
Salud Carbajal (D-CA)
JOHN LARSON (D-CT)
SHEILA JACKSON LEE (D-TX)
Madeleine Dean (D-PA)
Thomas Suozzi (D-NY)
NYDIA VELAZQUEZ (D-NY)
Mike Levin (D-CA)
Theodore Deutch (D-FL)
ELEANOR NORTON (D-DC)
William Timmons (R-SC)
KEVIN BRADY (R-TX)
David McKinley (R-WV)
Jefferson Van Drew (R-NJ)
KEN CALVERT (R-CA)
William Keating (D-MA)
Mario Diaz-Balart (R-FL)

Subjects

Drug safety, medical device, and laboratory regulation
Drug therapy
Government information and archives
Health care coverage and access
Health programs administration and funding
Health promotion and preventive care
Higher education
Medical research
Medical tests and diagnostic methods
Neurological disorders
Prescription drugs
Public-private cooperation
Research administration and funding
Research and development
Social work, volunteer service, charitable organizations

Became law: Pub. L. 117-79

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.